Lifecore Biomedical
LFCR
94 hedge funds and large institutions have $376M invested in Lifecore Biomedical in 2017 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 6 closing their positions.
48,700% more call options, than puts
Call options by funds: $488K | Put options by funds: $1K
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
25% more capital invested
Capital invested by funds: $301M → $376M (+$74.8M)
19% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 27
9% more funds holding
Funds holding: 86 → 94 (+8)
0.67% more ownership
Funds ownership: 92.04% → 92.71% (+0.67%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Walthausen & Co
Malta,
New York
|
+$2.71M |
| 2 |
RA
Royce & Associates
New York
|
+$2.46M |
| 3 |
AG
Algert Global
San Francisco,
California
|
+$1.89M |
| 4 |
Two Sigma Investments
New York
|
+$723K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$537K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
-$2.14M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$2.03M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$1.49M |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$1.01M |
| 5 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$821K |
LFCR Hedge Fund Activity: Q2 2017 in Review
94 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q2 2017, worth a combined $376M — up 25% from $301M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new LFCR positions and 6 closed out — a net gain of 8 holders — while 32 added to existing stakes and 27 trimmed.
The largest buyer was Walthausen & Co, opening a new position worth an estimated $2.71M. The largest seller was Ariel Investments, cutting an estimated $2.14M.
- 94 institutional investors held Lifecore Biomedical (LFCR) as of Q2 2017, up from 86 in Q1 2017.
- Funds reported $376M of Lifecore Biomedical stock for Q2 2017, up 25% quarter-over-quarter.
- 14 funds opened new Lifecore Biomedical positions in Q2 2017 and 6 closed out, a net change of +8 holders.
- The largest Lifecore Biomedical buyer in Q2 2017 was Walthausen & Co, an estimated $2.71M added.
- The largest Lifecore Biomedical seller in Q2 2017 was Ariel Investments, an estimated $2.14M sold.
Based on aggregated 13F filings for Q2 2017.